End-to-end respiratory Strados Labs offers a full-spectrum respiratory endpoint solution for clinical trials, presenting a turnkey opportunity to upsell integrated respiratory measurement capabilities to sponsors seeking consolidated data and streamlined vendor management.

Acquisition momentum Recent consolidation with NuvoAir assets and ongoing collaborations indicate a growing market position and expanded capabilities that can be leveraged to pursue new life sciences clients needing robust, scalable respiratory endpoints across Phase I to IV.

Clinical partnerships Strategic partnerships with renowned centers such as Beth Israel Deaconess Medical Center and collaborations with ATS events offer warm introductions to potential sponsors and access to early-adopter sites for pilot programs and case studies.

Chronic disease focus Development of wearables for chronic respiratory conditions points to cross-sell opportunities with pharma companies targeting COPD and asthma therapies, enabling continuous monitoring data to support real-world evidence and endpoint validation.

Global and scalable With global operational reach and Phase I through IV experience, Strados can position as a scalable, single-point solution for multinational trials, appealing to sponsors seeking consistent endpoints across diverse geographies.